Glucagon-like peptide-1 receptor (GLP-1R) signaling ameliorates dysfunctional immunity in COPD patients

BACKGROUND: The glucagon-like peptide-1 receptor (GLP-1R) agonist – liraglutide (LIR) – is an insulin secretagogue for the treatment of diabetes and has been proven to have therapeutic potential in the treatment of COPD. Evidence suggested that activating GLP-1R signaling might have immunomodulating...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingwen, Yi, Huahua, Zhao, Chunliu, Zhang, Yifan, Zhu, Liying, Liu, Bing, He, Ping, Zhou, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186765/
https://www.ncbi.nlm.nih.gov/pubmed/30349227
http://dx.doi.org/10.2147/COPD.S175145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186765/
https://www.ncbi.nlm.nih.gov/pubmed/30349227
http://dx.doi.org/10.2147/COPD.S175145

Ejemplares similares